{
    "Rank": 623,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT02195453",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "yl-yxb08-lcsyfa-201302"
                },
                "Organization": {
                    "OrgFullName": "Shandong Cancer Hospital and Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer",
                "OfficialTitle": "A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "July 2014",
                "OverallStatus": "Unknown status",
                "LastKnownStatus": "Not yet recruiting",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "August 2014"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "September 2016",
                    "PrimaryCompletionDateType": "Anticipated"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "December 2016",
                    "CompletionDateType": "Anticipated"
                },
                "StudyFirstSubmitDate": "July 7, 2014",
                "StudyFirstSubmitQCDate": "July 17, 2014",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "July 21, 2014",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "July 17, 2014",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "July 21, 2014",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Jinming Yu",
                    "ResponsiblePartyInvestigatorTitle": "Shandong Cancer Hospital and Institute",
                    "ResponsiblePartyInvestigatorAffiliation": "Shandong Cancer Hospital and Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Shandong Cancer Hospital and Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Peking University Cancer Hospital & Institute",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "The purpose of this study is to observe quality of life and treatment side effects in patients with advanced non small cell lung cancer (NSCLC) receive chemotherapy and Yangzhengxiaoji capsule."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Non-Small Cell Lung Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Non-small cell lung cancer",
                        "FACT-L scale",
                        "Yangzhengxiaoji"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 4"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Parallel Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "Triple",
                        "DesignWhoMaskedList": {
                            "DesignWhoMasked": [
                                "Participant",
                                "Care Provider",
                                "Investigator"
                            ]
                        }
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "520",
                    "EnrollmentType": "Anticipated"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Yangzhengxiaoji Capsule",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Gemcitabine or Pemetrexed\n\nCisplatin\n\nYangzhengxiaoji Capsule four granules t.i.d po",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Yangzhengxiaoji Capsule"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Placebo Capsule",
                            "ArmGroupType": "Placebo Comparator",
                            "ArmGroupDescription": "Gemcitabine or Pemetrexed\n\nCisplatin\n\nPlacebo Capsule four granules t.i.d po",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Placebo Capsule"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Yangzhengxiaoji Capsule",
                            "InterventionDescription": "Gemcitabine 1000mg/m\u00b2 or Pemetrexed 500mg/m\u00b2 IV drip on D1 and D8,21 days for a cycle.\n\nCisplatin 75mg/m\u00b2 IV drip for one day or two-three days total injection,21 days for a cycle.\n\nYangzhengxiaoji Capsule four granules t.i.d po.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Yangzhengxiaoji Capsule"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Placebo Capsule",
                            "InterventionDescription": "Gemcitabine 1000mg/m\u00b2 or Pemetrexed 500mg/m\u00b2IV drip on D1 and D8,21 days for a cycle.\n\nCisplatin 75mg/m\u00b2 IV drip for one day or two-three days total injection, 21 days for a cycle.\n\nPlacebo Capsule four granules t.i.d po.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Placebo Capsule"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Functional Assessment of Cancer Therapy-Lung scale",
                            "PrimaryOutcomeTimeFrame": "84day"
                        },
                        {
                            "PrimaryOutcomeMeasure": "Lung Cancer Symptom Scale",
                            "PrimaryOutcomeTimeFrame": "84day"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Anti-cancer drugs common grading evaluation of adverse reaction",
                            "SecondaryOutcomeTimeFrame": "84day"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Completion of chemotherapy",
                            "SecondaryOutcomeTimeFrame": "84 day"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Objective response rate",
                            "SecondaryOutcomeTimeFrame": "84day"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Progression-free survival",
                            "SecondaryOutcomeTimeFrame": "84 day"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion criteria:\n\nHistology and/or cytology confirmed stage \u2163 NSCLC patients;\nWith at least one measurable solid tumor (RECIST standard version 1.1): tumor >=10 mm in diameter on CT or MRI images, or lymph node >=15 mm in diameter on CT or MRI images;\nEastern Cooperative Oncology Group(ECOG) score 0-1, expectant survival > 3 months;\nAge: 18-70 years;\n\nNormal organ function:\n\nBone marrow: neutrophils (ANC) count>=1.5\u00d710^9/L, Platelets count>=100\u00d710^9/L, hemoglobin>=90g/L\uff1bRenal function, serum creatinine<=1.5 mg/dl, and/or creatinine clearance or>=60 ml/min; Liver function: total serum bilirubin levels <= 1.5 times the upper limit of normal (ULN), serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT)<=2.5 times the ULN, if abnormal liver function caused by the underlying malignancy, the AST and ALT >=5 times ULN;\n\nFor patients with brain metastases, bone metastases or pleural effusion, systemic chemotherapy is proposed after the effective local treatment to control symptoms;\nInformed consent.\n\nExclusion criteria:\n\nClinically significant hepatic dysfunction: AST or ALT > 2.5 times the ULN, total serum bilirubin levels > 1.5 times the ULN; clinically significant renal insufficiency: serum creatinine > 1.5 times the ULN;\nSevere heart disease: New York Heart Association class \u2162-IV class of heart failure, unstable angina, myocardial infarction, coronary revascularization six months before randomization;\nSpleen resection or combined with other severe hematopoietic system diseases;\nUncontrolled diabetes, hypertension (above 180/120mmHg), infection or severe gastrointestinal ulcers;\nHistory or present with other cancer, except for non melanoma skin cancer, cervical cancer in situ and other cured cancer for at least 5 years;\nMental illness, without legal capacity or limited capacity;\nPregnancy, lactation or patients with pregnancy plan;\nParticipated in other clinical trail in the past 1 months or participating in other trail now;\nOther unsuitable condition decided by the investigator.",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "MaximumAge": "70 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "CentralContactList": {
                    "CentralContact": [
                        {
                            "CentralContactName": "Ligang Xing, M.D.",
                            "CentralContactRole": "Contact",
                            "CentralContactPhone": "18053100188",
                            "CentralContactEMail": "xinglg@gmail.com"
                        }
                    ]
                },
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Jinming Yu, PhD",
                            "OverallOfficialAffiliation": "Shandong Cancer Hospital and Institute",
                            "OverallOfficialRole": "Study Chair"
                        },
                        {
                            "OverallOfficialName": "Jie Wang, PhD",
                            "OverallOfficialAffiliation": "Biejing Cancer Hospital",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000008175",
                            "ConditionMeshTerm": "Lung Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000002289",
                            "ConditionMeshTerm": "Carcinoma, Non-Small-Cell Lung"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000012142",
                            "ConditionAncestorTerm": "Respiratory Tract Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000013899",
                            "ConditionAncestorTerm": "Thoracic Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000008171",
                            "ConditionAncestorTerm": "Lung Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012140",
                            "ConditionAncestorTerm": "Respiratory Tract Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000002283",
                            "ConditionAncestorTerm": "Carcinoma, Bronchogenic"
                        },
                        {
                            "ConditionAncestorId": "D000001984",
                            "ConditionAncestorTerm": "Bronchial Neoplasms"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M10862",
                            "ConditionBrowseLeafName": "Lung Neoplasms",
                            "ConditionBrowseLeafAsFound": "Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5236",
                            "ConditionBrowseLeafName": "Carcinoma, Non-Small-Cell Lung",
                            "ConditionBrowseLeafAsFound": "Non-Small Cell Lung Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M5224",
                            "ConditionBrowseLeafName": "Carcinoma",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14669",
                            "ConditionBrowseLeafName": "Respiratory Tract Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M16348",
                            "ConditionBrowseLeafName": "Thoracic Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M10858",
                            "ConditionBrowseLeafName": "Lung Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M14667",
                            "ConditionBrowseLeafName": "Respiratory Tract Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M5230",
                            "ConditionBrowseLeafName": "Carcinoma, Bronchogenic",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4950",
                            "ConditionBrowseLeafName": "Bronchial Neoplasms",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC08",
                            "ConditionBrowseBranchName": "Respiratory Tract (Lung and Bronchial) Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M5872",
                            "InterventionBrowseLeafName": "Cisplatin",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M2986",
                            "InterventionBrowseLeafName": "Gemcitabine",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M264",
                            "InterventionBrowseLeafName": "Pemetrexed",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}